Online gateways such as Authorize.net and NMI support research-peptide and SARMs ecommerce with tokenization and fraud tooling for one-time orders.
High-risk merchant account
Peptide Merchant Accounts for Research-Use-Only Sellers
Research peptides, SARMs, and research chemicals lose accounts on reviewer discretion far more often than on a published rule. An account can clear signup and then close once someone reads the product line. Midnight Payments underwrites that exposure up front, instead of discovering it after a freeze.
24-hr approval
1,600+ U.S. businesses served by our network
$4.7B+ processed across our network
90%+ of legitimate merchants approved across our acquiring network
What a peptide merchant account is, and who provides one.
A peptide merchant account is a dedicated card-processing account underwritten for a research-peptide, SARMs, or research-chemical storefront, with its own merchant ID rather than a slot in a pooled aggregator account. Midnight Payments places these accounts through acquiring banks that knowingly board the category, so the research-use-only labeling, certificates of analysis, and marketing claims are read before the first transaction instead of at the first review.
A peptide payment processor is the provider that places and runs that account, together with the gateway behind the checkout, and for this category the two are chosen together. Mainstream platforms are not built for the category, and the ones that do not name it still close accounts under broad discretion, so what a peptide seller needs is a processor that prices the payment risk on the file in front of it. US, Canadian, and international peptide sellers are accepted, with no minimum monthly volume, and most complete applications are approved and processing within 24 hours.
Research-peptide sellers are dropped on reviewer discretion, not a published rule.
Most published policies do not name the category outright, which is what makes the exposure hard to see in advance. Stripe prohibits "incorrectly labeled research chemicals," so the entry turns on the labeling rather than the product. Square lists no peptide or research-chemical category at all and still terminates peptide sellers. Adyen names peptides explicitly but places them in a restricted tier that needs extra documentation, and Wise bans them outright. The practical result is that an account can clear signup, process for months, and then close once a reviewer reads the product line or finds a dosing claim.
Research peptides are not FDA-approved for human use, and FDA warning letters have gone to sellers whose marketing crossed into human-consumption or dosing claims. A research-use review looks at the labeling posture, the disclaimers, age-gating, and the refund and dispute profile before terms are set, instead of approving on a clean signup form and terminating after the first compliance flag.
A claim-risk termination in the research-chemical category can put a peptide seller on the MATCH or TMF list, where most processors stop returning calls. see your MATCH or TMF options.
If the current processor is already expensive, unstable, or holding funds, start with a statement review. The useful comparison is what determines your rate against the costs you are already paying.
Get ApprovedCapability proof
Research-use-aware underwriting for peptide and SARMs ecommerce
Peptide processing turns on the compliance posture, not the billing model. The account is reviewed against the research-use-only framing, the marketing claims, and the documentation behind the product line, so the labeling and FDA-exposure questions are settled during underwriting rather than surfacing as a later account event.
Research-use-only labeling, age-gating, and the absence of human-consumption or dosing claims are reviewed up front, because that posture is what underwriting and the FDA both check.
Certificates of analysis and clear research-use disclaimers are treated as core approval documentation, not paperwork requested after the account is already at risk.
Billing descriptors and research-use disclaimers are set up at boarding to match what underwriting approved, with age-verification support where the category requires it.
Gateways
Authorize.net / NMI / USAePay / PayTrace
Related processing capabilities for this page:
The peptide program
Built for peptide sellers who need the account to hold.
Peptide, SARMs, and research-chemical merchants are accepted worldwide, as US, Canadian, or international entities, and international merchants settle in their own currency where the rail supports it. There is no minimum monthly volume, so a first-account seller and an established brand can both apply, each priced on its own file.
Reserve-free options are available for some merchants and categories, and where a reserve applies it is disclosed in writing up front. The rate, the reserve structure, and the settlement timing are set out in writing before you sign, and high-risk rates run above standard retail. There is no long-term contract, and the exit terms are disclosed up front. Where volume supports it, the account runs on more than one acquiring bank, so a pause on one relationship does not stop revenue on the other.
Peptide merchant accounts
No minimum monthly volume requirement
24 hr approved and processing, most complete applications
Worldwide US, Canadian, and international entities
Reserve-free options are available for some merchants and categories. Any reserve, the rate, and the settlement timing are set out in writing before you sign.
Already processing? What changes when you switch.
If you are already processing, you are not asking what a merchant account is. You have an account, often on one acquirer and sometimes carrying a reserve, and you want to know what a move looks like before the next re-review. These are the questions that decide it.
- Redundancy
- Where volume supports it, your business is set up with more than one acquiring bank, so a pause on one account does not stop revenue on the other. Redundancy is easiest to set up at boarding, and adding a second acquiring relationship later depends on volume and underwriting.
- Migration
- You keep operating on the current account while the new one is underwritten and integrated, and volume moves over once the new account is live, so the switch is planned around the current account rather than around a gap between the two.
- Second account
- Keeping the current processor and adding a second account is often the right structure for a peptide seller. Many merchants keep a mainstream processor for clearly low-risk items and route the research-use catalog to the dedicated account.
- Reserves
- Reserve-free options exist for some merchants and categories. Where a reserve applies it is disclosed in writing up front, and a clean chargeback record is the argument for reducing or releasing it.
- Volume
- The account is underwritten to the volume you declare, so declare it accurately. Growth you projected is what the account was sized for, and a material change is worth telling the reviewer about before it lands. Bring three months of statements and the reviewer prices the file you actually run.
- Gateway
- A switch does not usually mean a rebuild. Compatible gateways such as Authorize.net and NMI carry the storefront, and the integration work is stated before you commit.
How approval review works.
Start your application
Start your application with your catalog, monthly volume, and what happened with your last processor. The merchant application and the document request follow by email, with certificates of analysis, research-use-only labeling, and your age-verification setup at checkout on the list.
Site copy is part of the review
Your product pages are read alongside the COAs, because human-consumption, dosing, or injection claims are what move a research-use catalog into a category no processor will place.
Terms come back in writing
Pricing is quoted for your business from your statement and risk profile, not from a rate card, and high-risk rates run above standard retail. The rate, any reserve structure, and the settlement timing are set out in writing before you sign, with no long-term contract.
Checkout goes live
Gateways such as Authorize.net and NMI carry research-peptide ecommerce, with age-gating and research-use disclaimers configured as part of the checkout rather than bolted on.
What you will need for review.
Documents vary by risk profile, but every application starts with the business basics and then adds category-specific proof.
Standard documents
- Completed merchant requisition form
- W9
- ABA/routing number, account number, and settlement name on account
- Business license
Peptide add-ons
- Research-use-only labeling and product disclaimers
- Certificates of analysis (COAs) for the compounds sold
- Website copy showing no human-consumption, dosing, or injection claims
- Age-verification details at checkout
- 3 months of prior processing statements
Peptide merchant account FAQ.
These answers are specific to peptide. For cross-cutting approval, pricing, reserve, and gateway questions, see the full FAQ.
Can you process research peptides, SARMs, and research chemicals?
Yes. Research peptides, SARMs, and research chemicals sold for research use only can be reviewed when the labeling, certificates of analysis, and marketing copy support that posture. Underwriting reads the compliance framing and the dispute profile, rather than approving on a clean signup form and closing the account once a reviewer gets to the product line.
How is a peptide account different from a nutraceutical or supplement account?
A supplement account covers ingestible dietary products marketed for human consumption under DSHEA, often on subscriptions. A peptide account covers research compounds sold for research use only, with no human-use claims and an FDA-drug gray area. The underwriting and compliance review are different, so the two are kept on separate accounts.
Will human-consumption or dosing claims affect approval?
Yes, directly. Marketing that describes dosing, injection, or human use moves the product from research use into unapproved-drug territory, which is the exact line FDA warning letters target. Keeping the site, labels, and disclaimers strictly research-use-only is part of staying approved, and that copy is reviewed during underwriting.
Do you require certificates of analysis?
Certificates of analysis for the compounds sold are expected during review. They show product identity and purity and support the research-use framing, which helps underwriting separate a documented research-supply business from an unlabeled research-chemical seller making health claims.
Can I get approved after Stripe or PayPal shut down my peptide store?
Yes. A prior shutdown is common for research-peptide sellers, because mainstream platforms often board first and review later, and the category can surface at the first review or dispute. Underwriting reads your transaction profile, product line, labeling, and compliance materials instead of repeating the decline, and a clean research-use posture strengthens the application. A prior termination narrows the options and affects pricing, but it is not automatically disqualifying.
Does FDA exposure mean a peptide account cannot be approved?
Not automatically, but a merchant account is never a judgment that your model is legal. These compounds are not FDA-approved for human use, and a research-use-only label does not by itself make a sale compliant; the FDA can still treat research chemicals sold to consumers as unapproved drugs. Underwriting prices the payment and dispute risk, not the legality of your business, which is on you and your counsel. A clean research-use posture with proper labeling and COAs is what keeps the payment side reviewable rather than an automatic decline.
Can I get a peptide merchant account outside the United States?
Yes. Peptide, SARMs, and research-chemical sellers are accepted as US, Canadian, or international entities, and international merchants settle in their own currency where the rail supports it. The core materials reviewed are the same wherever the entity sits, meaning the labeling posture, certificates of analysis, marketing claims, and dispute profile, while the banking and settlement setup depends on the entity location and the rail.
Is there a minimum monthly volume for a peptide merchant account?
No. There is no minimum monthly volume requirement for peptide merchant accounts, so a first-account seller with no processing history and an established brand moving real volume can both apply, each priced on its own file. A new seller is read on the storefront, the labeling, the certificates of analysis, and the bank and entity match rather than on statements it does not have yet.
Will I need a rolling reserve on a peptide account?
Sometimes. A reserve is a percentage of volume the acquiring bank holds for a set window against future disputes, and it is common for newer high-risk accounts or those without processing history. Reserve-free options are available for some peptide merchants and categories, and where a reserve applies it is disclosed in writing before you sign, together with the rate and the settlement timing. A clean chargeback record is the case for reducing or releasing it later.
How fast does a peptide account settle?
Settlement timing depends on the rail and the merchant, and it is set out in writing before you sign rather than discovered on the first statement. What the timing is and whether a reserve applies are part of the written terms, and any later reduction of a reserve depends on the record you build, so a research-supply seller can plan cash flow around a schedule it has actually seen.
Get reviewed
Get research peptides and SARMs reviewed by underwriting that reads the research-use posture before the first transaction.
Share your vertical, monthly volume, current processor status, and any recent statements. Midnight Payments will route the review toward a merchant account fit for the actual risk.